The concern of generic challenges has consistently loomed around copyright’s famous drug, Viagra, raising questions about the prospects of similar medicinal ventures. While initial periods saw substantial gains, the exclusivity end has opened the path for less expensive copies, potentially lowering revenue and presenting a real hazard for investo